Florian Malchers

Florian Malchers

Auto-generated profile, based on publicly available information

Florian Malchers

University of Cologne 4 Institute of Biochemistry I, Medical Faculty & CECAD Cluster of Excellence Cologne, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FMFlorian Malchers
Florian Malchers
LNLucia Nogova
Lucia Nogova
MAMartijn H.A. van Attekum
Martijn H.A. van Attekum
LMLukas Maas
Lukas Maas
JBJohannes Brägelmann
Johannes Brägelmann
RTRoman K. Thomas
Roman K. Thomas
The discovery of frequent 8p11-p12 amplifications in squamous cell lung cancer (SQLC) has fueled hopes that FGFR1, located inside this amplicon, might be a therapeutic target. In a clinical trial, only 11% of patients with 8p11 amplification (detected by FISH) responded to FGFR kinase inhibitor treatment. To understand the mechanism of FGFR1 dependency, we performed deep genomic characterization of 52 SQLCs with 8p11-p12 amplification, including 10 tumors obtained from patients who had been treated with FGFR inhibitors. We discovered somatically altered variants of FGFR1 with deletion of exons 1–8 that resulted from intragenic tail-to-tail rearrangements. These ectodomain-deficient FGFR1 variants (ΔEC-FGFR1) were expressed in the affected tumors and were tumorigenic in both in vitro and in vivo models of lung cancer. Mechanistically, breakage-fusion-bridges were the source of 8p11-p12 amplification, resulting from frequent head-to-head and tail-to-tail rearrangements. Generally, tail-to-tail rearrangements within or in close proximity upstream of FGFR1 were associated with FGFR1 dependency. Thus, the genomic events shaping the architecture of the 8p11-p12 amplicon provide a mechanistic explanation for the emergence of FGFR1-driven SQLC. Specifically, we believe that FGFR1 ectodomain–deficient and FGFR1-centered amplifications caused by tail-to-tail rearrangements are a novel somatic genomic event that might be predictive of therapeutically relevant FGFR1 dependency.

3 November 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
LNLucia Nogova
Lucia Nogova
FMFlorian Malchers
Florian Malchers
Axel HillmerAxel Hillmer
Axel Hillmer
ITInken Terjung
Inken Terjung
HSHeather Scharpenseel
Heather Scharpenseel
JWJürgen Wolf
Jürgen Wolf
Purpose: FGFR alterations occur in approximately 2% of patients with non–small cell lung cancer (NSCLC), predominantly in squamous cell histology (sqNSCLC). We evaluated the efficacy of the selective FGFR1–4 inhibitor erdafitinib in patients with FGFR-altered NSCLC. Patients and Methods: Patients with NSCLC were prescreened within the national Network Genomic Medicine (nNGM) for FGFR mutations/fusions. Patients were treated with erdafitinib after assessment of every alteration in the study-specific molecular board in three cohorts: (i) high-confidence activating FGFR fusions, (ii) high-confidence activating FGFR mutations, and (iii) low-confidence activating FGFR alterations. The primary objective was the best confirmed overall response rate on erdafitinib in cohorts 1 and 2 assessed by RECIST 1.1 every 8 weeks. Statistical analysis was based on the Simon two-stage minimax design. Results: Between July 2019 and September 2022, 44,537 patients were prescreened in nNGM, 26 patients were enrolled in stage I of the Simon design, and 4 patients failed screening. Most patients were male (77%) and had sqNSCLC (73%). All patients were current or previous smokers. Of 22 patients on erdafitinib, 7 were treated in cohort 1, 8 were treated in cohort 2, and 7 were treated in cohort 3. In cohort 1, 2 of 7 patients achieved partial response (PR). However, one PR remained unconfirmed. The best response in cohort 2 was stable disease. The most observed adverse events of any grade were hyperphosphatemia (in 45.5%) and diarrhea and dry mouth (both in 31.8% of patients). Conclusions: According to the first stage of the two-stage Simon design, erdafitinib showed preliminary efficacy in NSCLC with FGFR fusions. Further molecular and clinical data are needed to evaluate the efficacy of FGFR inhibition in NSCLC, especially in patients with FGFR mutations.



20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LNLucia Nogova
Lucia Nogova
FMFlorian Malchers
Florian Malchers
EBElisabeth Bitter
Elisabeth Bitter
SMSebastian Yves Friedrich Michels
Sebastian Yves Friedrich Michels
RFRieke Nila Fischer
Rieke Nila Fischer
JWJuergen Wolf
Juergen Wolf
E20664 Background: Fibroblast growth factor receptor 1 ( FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in FGFR1amplified sgNSCLC treated with dose ≥ 100mg. To identify underlying mechanisms of resistance, we analyzed tumor tissues of selected patients. Methods: Within the phase I BGJ398 study, patients (pts) with FGFR1amplified sqNSCLC were treated orally with escalating dose (5 to 150mg) of BGJ398 once daily (QD) or 50mg twice a day. In the expansion phase, pts received BGJ398 either continuously QD or on a 3-weeks on/1-week off schedule. CT scans for response were performed every 8 weeks. Available tumor tissue of pts treated with BGJ398 at our center was analyzed using hybrid capture–based massively parallel sequencing (CAGE). Results: Twenty-one pts with FGFR1 amplified sqNSCLC were treated with ≥ 100mg BGJ398 at our site. As best response, 3 pts showed partial response (PR), 7 pts stable disease (SD) and 7 pts progressive disease (PD). Two pts withdrew their consents and 2 pts died ahead of first CT scan: one due to infection and one due to sudden death. We performed CAGE covering 256 genes on 9 patients: on 3 pts with PR, 2 pts with SD, 2 pts with PD and 2 pts who died before first CT scan. All analyzed patients harbored mutations in TP53. Additionally, we detected two CDKN2A (one patient with PR and one patient who died before first CT) and three MLL2 stop codon and frame shift mutations (two patients with SD and one patient with PD). Of interest, we identified three patients with two canonical (one patient with SD and one patient who died before first CT) and one non-canonical mutations in PIK3CA(one patient with SD). Conclusions: In our analysis, MLL2 and PIK3CA mutations seem to have a negative impact on response in FGFR1 amplified pts treated with BGJ398. Further analysis with higher patient number is needed to identify the role of MLL2 and PIK3CA mutations in FGFR1 amplified sqNSCLC. Clinical trial information: NCT01004224.

12 February 2026 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LWLisa Werr
Lisa Werr
JBJana Boland
Jana Boland
JPJosephine Petersen
Josephine Petersen
FIFiorella Iglesias Iglesias
Fiorella Iglesias Iglesias
SHStefanie Höppner
Stefanie Höppner
MFMatthias Fischer
Matthias Fischer
Fibroblast growth factor receptor 1 ( FGFR1 ) is recurrently mutated at p.N546 in neuroblastoma. We examined whether mutant FGFR1 is an oncogenic driver, a predictive biomarker, and an actionable vulnerability in this malignancy. FGFR1 mutations at p.N546 were associated with high-risk disease and rapid tumor progression, resulting in dismal outcome for these patients. Ectopic expression of FGFR1 N546K induced constitutive downstream signaling and IL-3–independent growth in Ba/F3 cells, indicating oncogene-addicted proliferation. In FGFR1 N546K ; MYCN transgenic mice, neuroblastoma developed within the first days of life, with fatal outcome within 3 weeks, reflecting the devastating clinical phenotypes of patients with FGFR1 -mutant, high-risk neuroblastoma. Treatment with FGFR inhibitors impaired proliferation and pathway activation in FGFR1 N546K -expressing Ba/F3 and patient-derived FGFR1 N546K -mutant neuroblastoma cells and inhibited tumor growth in FGFR1 N546K ; MYCN transgenic mice and in a chemotherapy-resistant, patient-derived xenograft mouse model. In addition, partial regression of FGFR1 N546K -mutant tumor lesions occurred upon treatment with the FGFR inhibitor futibatinib and low-intensity chemotherapy in a patient with refractory neuroblastoma. Together, our data demonstrate that FGFR1 N546K is a strong oncogenic driver in neuroblastoma associated with failure of current standard chemotherapy and suggest potential clinical benefit of FGFR-directed therapies in patients with high-risk mutant FGFR1 .